Tesamorelin: A GHRH Analogue With a Specific FDA Approval and Defined Limits

The short version

Tesamorelin is a synthetic version of a hormone the hypothalamus naturally produces: growth hormone-releasing hormone (GHRH). It is a 44-amino-acid peptide modified at one end to resist an enzyme that would otherwise break it down quickly, giving it a longer useful lifespan in circulation. The FDA approved tesamorelin in 2010 for a specific, narrow indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy — a condition in which antiretroviral drugs cause abnormal fat redistribution ^[14].

That approval is the key fact to hold. Tesamorelin works — in that specific population, the evidence is solid and consistent across multiple trials and a 2026 meta-analysis ^[13]. But the approval does not extend beyond HIV-associated lipodystrophy. Using it in any other context — general visceral fat reduction, anti-aging, cognitive enhancement, or other metabolic conditions — is off-label and investigational. Tesamorelin is also WADA-prohibited in sport. This page summarizes the published evidence and its actual scope. It lists no dose.

What it is

Tesamorelin acetate (also known by the research designation TH9507) is a synthetic 44-amino-acid analogue of human GHRH(1-44)-NH2. The key structural modification is a trans-3-hexenoic acid group conjugated to the N-terminus. That modification confers resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), which would otherwise rapidly degrade native GHRH. This extends plasma stability compared to the natural hormone. Empirical formula of the free base: C221H366N72O67S.

Tesamorelin acts upstream in the growth-hormone axis. Rather than supplying exogenous growth hormone directly, it tells the pituitary to produce more of the body's own GH — preserving the pulsatile, rhythmic pattern of normal GH secretion. This mechanistic distinction from recombinant GH is relevant to its metabolic profile. Supplied clinically as the acetate salt; research-grade material is supplied for laboratory use only.

How it works

Tesamorelin binds to the growth hormone-releasing hormone receptor (GHRH-R) on anterior-pituitary somatotroph cells — the cells that manufacture and store growth hormone. Binding activates the Gs protein, which raises intracellular cAMP via adenylyl cyclase, which activates PKA, which triggers both GH synthesis and the pulsatile GH release that characterizes normal physiology ^[17].

The released GH travels to the liver, where it drives production of IGF-1. Both GH and IGF-1 then promote lipolysis — the breakdown of stored fat — with the effect landing preferentially in visceral adipose tissue: the metabolically active fat depot around the abdominal organs. This is the mechanism that makes tesamorelin a visceral fat-reduction agent rather than a general weight-loss drug.

A 2011 study in 13 healthy men established that tesamorelin raises overnight GH and IGF-1 substantially (mean overnight GH +0.5 µg/L, P=0.004; IGF-1 +181 µg/L, P<0.0001) while leaving fasting glucose and insulin-stimulated glucose uptake statistically unchanged ^[16]. The pulsatile mode of GH stimulation appears to preserve insulin sensitivity better than supraphysiological exogenous GH administration.

What the research shows

FDA approval foundation (2008, 2010). A 52-week program (tesamorelin versus placebo, HIV patients with abdominal fat accumulation, n=273 vs n=137) showed sustained visceral adipose tissue (VAT) reduction of -18% over 52 weeks (P<0.001 vs baseline) without clinically significant glucose changes. Visceral fat reaccumulated after discontinuation ^[17]. This study underpinned the 2010 FDA approval.

JAMA visceral fat and liver fat RCT (2014). In 50 antiretroviral-treated HIV adults (28 tesamorelin, 22 placebo), 6 months of tesamorelin 2 mg/day produced a treatment effect of -42 cm² in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) ^[15].

Endocrine mechanism in healthy men (2011). In 13 healthy men receiving 2 mg/day for 2 weeks, mean overnight GH increased by +0.5 µg/L (P=0.004) and IGF-1 by +181 µg/L (P<0.0001), with no statistically significant effect on insulin-stimulated glucose uptake ^[16]. Establishes the GH-pulsatility mechanism with clean metabolic safety in a healthy population.

2026 meta-analysis (five RCTs, HIV-associated lipodystrophy). Pooled analysis found tesamorelin reduced VAT (MD -27.71 cm², 95% CI -38.37 to -17.06; P<0.001), trunk fat (MD -1.18 kg), and hepatic fat fraction (MD -4.28%), while increasing lean body mass (MD +1.42 kg), all with P<0.001, and without serious adverse events ^[13].

Hepatic safety (NIH LiverTox, 2018). The NIH LiverTox monograph assigns tesamorelin a likelihood score of E — unlikely to cause clinically apparent liver injury — noting no reported attributable liver-injury cases and no de novo serum-enzyme elevations in the trials ^[14].

Reported effects, cautions & safety

Tesamorelin's approved-population evidence is robust. Its primary cautions are about scope and context.

Note: the research.json source material for tesamorelin includes no compiled community-anecdote data, so none are presented here. The cautions and controversies below are drawn from the cited literature and compliance record.

Scope of approval. FDA approval is limited to HIV-associated lipodystrophy. All other applications — general visceral fat reduction, non-HIV metabolic liver disease, cognitive enhancement, anti-aging — are off-label and investigational. The pivotal trials enrolled HIV-positive adults on antiretroviral therapy; generalizability to non-HIV populations is mechanistically plausible but not established by large RCTs ^[17][13].

Discontinuation rebound. Visceral fat reaccumulates within weeks of stopping tesamorelin. Benefits are contingent on continued dosing ^[17]. This is a documented feature of the mechanism, not a side effect.

IGF-1 elevation. Tesamorelin raises serum IGF-1, a growth factor. Trials showed no excess malignancy signal over 52 weeks, but long-term oncologic-safety data are limited, and active malignancy is a labeled contraindication ^[17].

Glucose perturbation. Modest glucose changes can occur; monitoring is warranted in individuals with prediabetes or existing dysglycemia, though dedicated type 2 diabetes trials found no significant HbA1c change ^[16].

WADA prohibition. Tesamorelin is prohibited in sport under WADA Prohibited List category S2 (peptide hormones, growth factors, related substances and mimetics) as a GHRH analogue, in- and out-of-competition.

Research-grade versus approved product. The approved product is a prescription drug for a specific HIV indication. Research-grade tesamorelin sold for laboratory use does not carry the purity, potency, or sterility oversight of the prescription product. These are not interchangeable. The LiverTox monograph is hepatic-injury focused and covers the approved clinical product, not research-channel material ^[14].

Where it fits in repair and metabolic research

Among the three compounds on this desk, tesamorelin is the only one with any regulatory approval — and that approval is narrow and specific. It acts upstream in the GH axis, stimulating the pituitary rather than supplying GH directly, and its effects on visceral fat in HIV lipodystrophy are the most rigorously documented in this trio ^[13][15][17]. Where BPC-157 is overwhelmingly preclinical and retatrutide is broadly investigational, tesamorelin occupies a precise middle ground: approved human data in one population, off-label territory everywhere else. That precision makes it a useful reference point for understanding what a peptide in this category looks like when it reaches the level of evidence that earns a regulatory decision. See the comparison page for a structured side-by-side view.